LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma was written by Mateos, Maria-Victoria;Weisel, Katja;De Stefano, Valerio;Goldschmidt, Hartmut;Delforge, Michel;Mohty, Mohamad;Cavo, Michele;Vij, Ravi;Lindsey-Hill, Joanne;Dytfeld, Dominik;Angelucci, Emanuele;Perrot, Aurore;Benjamin, Reuben;van de Donk, Niels W. C. J.;Ocio, Enrique M.;Scheid, Christof;Gay, Francesca;Roeloffzen, Wilfried;Rodriguez-Otero, Paula;Broijl, Annemiek;Potamianou, Anna;Sakabedoyan, Caline;Semerjian, Maria;Keim, Sofia;Strulev, Vadim;Schecter, Jordan M.;Vogel, Martin;Wapenaar, Robert;Nesheiwat, Tonia;San-Miguel, Jesus;Sonneveld, Pieter;Einsele, Hermann;Moreau, Philippe. And the article was included in Leukemia in 2022.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, 鈮? prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 mo (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem